Marker genes for determining renal toxicity
CA 2493860 A1 · Owner: Kehren, Jeanne · Inventors: Chibout, Salah-Dine; Imbert, Georges; Wolfgang, Curt Douglas
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Methods are disclosed for fast and accurate readout of kidney toxicity before it occurs and before it is demonstrated by histopathology examination. Ultimately this approach shall allow earlier compound selection. The twelve genes identified, namely Calbindin-D28k KIM-1, OPN, EGF, Clusterin, VEGF, OAT- K1, Aldolase A, Aldolase B, Podocin, Alpha-2u and C4 were grouped and , ultimately can be assessed in the form of a kit using PCR a high throughput , technology, in order to characterize and rank new compounds according to their anticipated general kidney toxicity. Also disclosed are methods for identifying agents useful in the treatment of kidney disease methods for , monitoring the …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 3, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 3, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 3, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.